United TherapeuticsUTHR Market cap $15.8B
About: United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Employees: 1,168
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
80% more funds holding in top 10
Funds holding in top 10: 10 [Q1] → 18 (+8) [Q2]
74% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 61
40% more capital invested
Capital invested by funds: $10.4B [Q1] → $14.6B (+$4.19B) [Q2]
9% more funds holding
Funds holding: 512 [Q1] → 557 (+45) [Q2]
7.17% more ownership
Funds ownership: 96.0% [Q1] → 103.17% (+7.17%) [Q2]
3% more repeat investments, than reductions
Existing positions increased: 195 | Existing positions reduced: 189
1% more call options, than puts
Call options by funds: $281M | Put options by funds: $279M
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Jefferies Eun Yang 0% 1-year accuracy 0 / 4 met price target | 21%upside $432 | Buy Maintained | 23 Sept 2024 |
Oppenheimer Hartaj Singh 36% 1-year accuracy 5 / 14 met price target | 62%upside $575 | Outperform Maintained | 28 Aug 2024 |
Wells Fargo Tiago Fauth 93% 1-year accuracy 13 / 14 met price target | 7%upside $380 | Overweight Maintained | 20 Aug 2024 |
HC Wainwright & Co. Andrew Fein 47% 1-year accuracy 56 / 118 met price target | 12%upside $400 | Buy Reiterated | 1 Aug 2024 |
B of A Securities Greg Harrison 43% 1-year accuracy 3 / 7 met price target | 21%downside $280 | Underperform Maintained | 1 Aug 2024 |
Financial journalist opinion
Based on 3 articles about UTHR published over the past 30 days